Treatment was initially approved in 2017 for the same indication in children aged 12 and up.
FDA Approves AstraZeneca’s Fasenra as Add-On Maintenance Therapy for Children Aged 6 to 11 with Severe Asthma
You May Also Like
Global Launch Strategies in the Current Political Climate
February 19, 2025
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
February 19, 2025
Navigating Distrust: Pharma in the Age of Social Media
February 18, 2025
+ There are no comments
Add yours